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1. Introduction 
On December 23, 1954, the first successful kidney transplantation was performed at the 
Peter Bent Brigham Hospital in Boston with the donor being an identical twin of the 
recipient [1]. This sentinel event marked one of the first in the history of modern medicine 
that a perfectly healthy individual underwent an invasive surgical procedure for the benefit 
of another. It also revealed that kidney donation and kidney transplantation were feasible 
and thus ushered the era of renal transplantation. Crossing immunological barriers between 
donor and recipient became the next major hurdle in the field. Over the past decades, 
advances in immunosuppression and crossmatch techniques have significantly improved 
the survival of renal transplants. Allograft survival has improved from 10% in the 1960’s to 
over 90% in the modern era [2,3].  
This chapter will introduce the basics of transplantation immunology with an emphasis on 
the HLA system and mechanisms for HLA typing. It will also provide an overview of 
different crossmatch techniques and also expound upon methods to determine sensitization 
to the donor. Lastly, it will introduce the basis for acute rejection, the diagnostic criteria that 
is currently employed, and noninvasive methods to diagnose acute rejection.  
2. HLA system 
The Human Leukocyte Antigen (HLA) is composed of proteins expressed on all nucleated 
cells encoded by a gene cluster called the major histocompatibility complex (MHC) and is 
the cornerstone of how mammals can differentiate between self and non-self. The work on 
MHC originated from Peter Gorer in the 1930’s where he identified a set of four blood-
group antigens [4]. Since these important findings, much research has been performed in 
investigating the MHC system and the equivalent H-2 system in mice. Understanding the 
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HLA system is critical to transplantation because differences in HLA between donor and 
recipient allow the immune system of a recipient to reject a donor’s kidney. The HLA 
system is divided into two major classes of molecules: class I and class II.  
2.1. HLA class I system 
There are three major alleles of the HLA class I genes: HLA-A, HLA-B, and HLA-C. The 
HLA class I molecule is a membrane-bound glycoprotein that is expressed on the surface of 
all nucleated cells and presents peptides for recognition by the host immune cells. The 
structure of the HLA class I molecule can be divided into the following regions: a 
cytoplasmic tail, a transmembrane segment, and an extracellular alpha component that has 
three external domains: a1, a2, and a3. In order to be able to present antigen to lymphocytes for 
recognition, the HLA class I molecule must associate with B2-microglobulin. Between the a1 
and a2 domains is a groove like structure that can bind peptides of 8 to 10 amino acids.  
To understand the process of presentation in the HLA class I system, we will use an 
example of an intracellular bacteria that has invaded a nucleated cell of the host. 
Presentation of antigen by an HLA class I molecule requires an important step called 
loading of the antigen on the HLA class I molecule.  Inside each cell is a protein-degrading 
machinery called the proteasome which constantly degrades proteins into amino acids. 
Following bacterial invasion, some of the bacterial proteins will be degraded by the cell’s 
proteasome. The short peptide segments of the bacterial proteins are loaded onto the groove 
of the host HLA class I molecule. The HLA class I molecule is then brought to the surface of 
the cell and can now present the peptide to the host’s circulating lymphocytes. If a 
lymphocyte recognizes the bacterial antigen in the groove of the host HLA class I molecule, 
it can become activated and can initiate a cascade of intracellular changes, resulting in the 
proliferation of lymphocytes that can specifically attack the infected cell. It is through the 
host HLA class I antigen processing and presentation that the immune system can eliminate 
cells infected with intracellular bacteria. If presented without the host HLA class I molecule, 
naked bacterial proteins are not recognized by the host immune system [4,5].  
For transplantation, this process can be summarized in a similar way. Just as the proteasome 
processes proteins associated with intracellular bacteria, it also degrades all proteins in a 
foreign cell including the HLA class I molecules. As such, donor leukocytes that travel along 
the kidney at the time of transplantation undergo the fate of an intracellular bacteria. They 
present peptides of the donor HLA class I molecule to circulating host lymphocytes. 
Lymphocytes recognize the donor peptides and mount a response against the foreign HLA 
class I molecule. 
2.2. HLA class II system 
An important difference between HLA class I molecules and HLA class II molecules is that the 
HLA class II molecules are expressed in a limited number of cell lines such as dendritic cells, 
macrophages, and B lymphocytes. Certain other cells like vascular endothelial cells and 
various epithelial and mesenchymal cells can be induced to express class II molecules. There 
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are 3 major alleles of the HLA class II genes: HLA-DP, HLA-DQ, and HLA-DR. The function of 
the HLA class II molecule is to present extracellular foreign antigens to the immune system.  
The structure of the HLA class II molecule can be divided into the following regions: a 
cytoplasmic tail, a transmembrane segment, and an extracellular alpha component that has 
two external domains. Unlike the HLA class I molecule, the HLA class II molecule is 
composed of a dimer. Once a dimer is formed, the extracellular units of the dimer create a 
groove like structure that can bind peptides for presentation. This peptide binding groove is 
the place where foreign antigens can be presented to lymphocytes. 
To understand the process of presentation in the HLA class II system, we will use an 
example of extracellular bacteria. A macrophage, which is one of the cell types that express 
HLA class II molecules, can endocytose an extracellular bacteria. The endocytosed bacteria 
fuse with lysosomes, which contain enzymes that will degrade peptides of the bacteria. 
Peptides from this degradation event are loaded onto the HLA class II molecules which are 
brought to the surface for display to the immune system.  The HLA class II molecules 
present the peptides to the host lymphocytes resulting in various immune responses that 
culminate in the killing of the bacteria.  
For transplantation, the immune response can be summarized in a similar way. Specialized 
recipient cells that express the HLA class II molecule routinely endocytose contents of their 
environment. As such, these specialized cells can endocytose the contents of donor cells 
which may include donor HLA class I or class II molecules. These peptides are subsequently 
loaded onto the HLA class II molecule and can now be presented to the recipient’s 
circulating lymphocytes.  
A major functional difference between the two classes of HLA is that the class I molecules 
present peptides derived from intracellular proteins to cytotoxic CD8 T cells, whereas class 
II molecules present peptides derived from extracellular proteins to CD4 T cells. After a 
kidney transplant, donor antigen presenting cells migrate to the draining lymph nodes of 
the recipient. The recipient CD4+T cells respond to donor class II HLA-peptide complex and 
the recipient CD8+T cells respond to donor class I HLA-peptide complex. This is called the 
direct pathway and is fundamentally different from the way the immune system responds 
to a foreign antigen. Contrary to MHC-restriction by which the T cells that respond to 
foreign peptides do so only when the foreign peptides are presented by antigen presenting 
cells expressing the same MHC as the responding T cells, T lymphocytes of the recipient 
respond and proliferative to donor derived non-self HLA molecules.  In the indirect 
pathway, the sequence of events is similar to the host response towards an extracellular 
pathogen; recipient’s antigen presenting cells internalize donor derived peptides and 
present as recipient HLA-donor peptide complex to the recipient lymphocyte [6]. 
2.3. HLA typing  
Determining the HLA make up of an individual is called HLA typing. The HLA system is 
extremely diverse with hundreds of known alleles for each HLA class molecule.  We have 
two alleles, one derived from each parent, for each HLA molecule. Alleles derived from each 
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parent that are transmitted together is called a haplotype. Matching or mismatching 
between donor and receipient is reported based on haplotypes for living related transplants 
and on individual antigens for deceased donor transplants. Typically, there are three major 
HLA alleles that are routinely assessed: 2 alleles of HLA-A, 2 alleles of HLA-B, and 2 alleles 
of HLA-DR. It is important to remember that, immunologically, a 6-antigen matched 
deceased donation is not the same as a 2-haploidentical living-related donation. Similarly, 
due to differences in minor histocompatibility antigens, donation between 2-haploidentical 
siblings is not the same as donation between identical twins. In the following sections, we 
will review the methods for determining the composition of the HLA antigen system of an 
individual. 
2.3.1. Serology based methods 
Serology based typing was the first method used to identify the HLA of an individual. This 
technique is similar to blood group typing. It utilizes viable lymphocytes of the individual to 
be typed. The lymphocytes are mixed with antisera that contain antibodies to a wide 
spectrum of HLA. Although simple, there are several limitations with this method. The 
coverage of HLA antigen screening is not comprehensive as antisera for corresponding HLA 
have been largely developed in Caucasian population. Variability exists in the production of 
antisera resulting in differences among laboratories. Viable lymphocytes are necessary for 
serology typing. Given these limitations and the significant decrease in cost for DNA typing 
methods, serology based methods have been largely supplanted [7,8]. 
2.3.2. DNA typing methods 
Currently, the major techniques in DNA typing include sequence-specific primers (SSPs), 
sequence-specific oligonucleotide probes (SSOPs), and sequencing-based typing (SBT). The 
SSP method takes advantage of the polymerase chain reaction (PCR) and the specificity of 
primers. A PCR will not undergo amplification unless the sequences of the primers are 
nearly perfect in binding. Primer sets have been designed in order to detect the variation in 
sequences for HLA typing. The SSP method can thus detect the HLA typing of an 
individual. Given the significant reduction in cost for PCR, the technique is inexpensive and 
can provide HLA typing in few hours. The SSOP method provides a complementary 
approach. The method utilizes 6 to 19 length nucleotide probes that will bind to DNA 
sequences specific to HLA alleles. The probes are labeled with a marker like digoxigenin 
that will allow for identification of HLA alleles. 
Because of increasing number of HLA alleles being identified, higher resolution methods 
have been developed. Both the SSP and SSOP methods can only identify known HLA 
alleles. In contrast, SBT method does not require prior knowledge of the HLA alleles and 
can reveal new alleles. This method does provide the most comprehensive understanding of 
an HLA typing but is time consuming and expensive.  Many centers utilize SSP method and 
SSOP method for routine identification of the typing of an individual [7,8,9].  
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2.4. HLA matching 
It was recognized that allograft survival was superior in siblings who shared the same 
serologically typed HLA when compared to non-matched deceased donor transplants. 
Given advances in immunosuppressive therapy and improved crossmatching techniques, 
transplantation across HLA barriers is now routinely performed. In the early 1990s, it was 
shown that there was an increased rate of one-year graft survival and estimated half-life for 
matched grafts compared with mismatched grafts [10]. Long term graft survival rather than 
early rejection is affected by the degree of HLA mismatch. As per the 2010 annual report of the 
Scientific Registry of Transplant Recipients, the five-year allograft survival for deceased donor 
kidney transplants was 77% with zero HLA mismatch and 67% with six HLA mismatch (3). 
Two haplotype matched living transplants are estimated to have a half life of approximately 30 
years while one haplotype matched living transplants have a half life of 18 years [11].  
In addition to the major HLA described above, minor antigens may play a significant role in 
allograft survival. An important antigenic molecule that is well described is the MHC class I 
polypeptide-related sequence A encoded by the MICA gene. The MICA gene is located on 
human chromosome 6 but unlike class I molecule, does not associate with beta-2-
microglobulin and thus does not present antigens like HLA class I molecules. However, it is 
highly polymorphic and over 50 antigens have been described. Transplant recipients who 
have antibodies to MICA have worse graft survival compared to those who do not [12,13,14]. 
3. Blood group matching 
In order to transplant a kidney, the same rules of blood transfusion apply. Thus, ABO blood 
group matching is the fundamental first step. Rh matching, however, is not required as Rh 
proteins are predominantly expressed only on red blood cells.  Aside from HLA matching, 
ABO incompatibility has been another successful barrier that has been crossed in renal 
transplantation. In Japan, over 1000 transplant patients have received ABO incompatible 
transplants with good allograft survival. One-year and 3-year graft survival rates in this 
cohort were 96% and 94%, respectively [15]. Desensitization protocols have been developed 
that include use of rituximab, splenectomy, or plasmapheresis to successfully achieve high 
rates of graft survival.  
4. Complement Dependent Cytotoxicity (CDC) crossmatch test 
The CDC crossmatch test was a landmark in vitro test that propelled transplantation into a 
new era. Developed by Paul Terasaki in the late 1960’s, it is still used today and is a 
prerequisite for any renal transplantation. The CDC crossmatch test essentially screens for 
preformed antibodies in the recipient that may immediately react against the donor. In this 
test, T lymphocytes are isolated from the donor and mixed with serum from the recipient. 
When preformed antibodies from the recipient recognize the HLA class I molecule, these 
antibodies bind to them. Following the addition of complement, the cells undergo lysis. A 
dye that penetrates lysed cells is utilized to detect the strength of the cell death. In contrast, 
if no antibodies in the recipient’s serum bind to the T-lymphocyes of the donor, complement 
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will not be activated and there will be no cell death. No dye will be taken up by the cells and 
the test is considered a negative reaction. The result of the crossmatch test is reported as the 
percentage of dead cells relative to live cells as determined by microscopy. The reading is on 
a semi-quantitative scale with 0 representing no dead cells, 2, 4, and 6 representing 
increasing severity of cell death, and 8 representing complete lysis of cells.  When there is 
greater than 20% cell lysis, the test is reported as positive and is generally considered a 
contraindication for transplantation [6]. 
The importance of the CDC crossmatch test in transplantation cannot be underscored. In 
Terasaki’s initial series, 24 out of 30 transplants that tested positive for the CDC crossmatch 
test had immediate allograft failure while only 4 out of 17 transplants that tested negative  
had immediate allograft failure [16]. Since the development of this test, hyperacute rejection 
with immediate allograft failure has largely disappeared.  
4.1. Significance of B lymphocyte CDC test 
At the present time, a positive CDC crossmatch test utilizing T lymphocytes of the donor is 
considered an absolute contraindication for kidney transplantation. T cells do not 
constitutively express HLA class II molecules. Hence, the result of a positive T lymphocyte 
crossmatch test generally reflects antibodies to HLA class I only. A positive CDC crossmatch 
test using B lymphocytes of the donor has different implications. B lymphocytes express 
both HLA class I and HLA class II molecules. A CDC crossmatch test that is positive against 
donor B lymphocytes but negative against donor T lymphocytes can be interpreted to 
represent a HLA class II antibody that reacts against the donor or to represent low levels of 
HLA class I antibodies against the donor. The expression of HLA class II molecule is not 
universal like HLA class I molecule and is limited to macrophages, dendritic cells, and B 
lymphocytes. A positive B lymphocyte CDC crossmatch test is not an absolute 
contraindication to proceeding with the transplantation. However, it has been associated 
with reduced long term graft survival [17]. A positive T lymphocyte CDC crossmatch in the 
presence of a negative B lymphocyte CDC crossmatch could possibly be a technical error 
related to B lymphocyte viability and is usually repeated [18].  
4.2. Advances in CDC testing 
In order to enhance the sensitivity of the CDC crossmatch test, anti-human globulin (AHG) 
has been utilized [6]. Efficient complement activation in the CDC crossmatch test depends 
not only on the antibody binding to the donor cells but also the concentration of antibodies 
on the surface of the cells. It is possible to have a false negative T lymphocyte CDC 
crossmatch test if the concentration of antibodies binding to the T lymphocytes is below the 
threshold for complement activation. Addition of AHG will enhance the concentration of 
antibodies if specific binding of antibodies are already present and thus increase the 
sensitivity of the CDC crossmatch test. 
As both IgG and IgM can fix complement, the CDC crossmatch test cannot distinguish IgG 
from IgM antibodies. IgM antibodies are usually autoantibodies. IgM antibody exists as a 
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pentamer that is held by disulfide bonds. Such disulfide bonds can be broken down by the 
use of the reducing agents like 2-mercaptoethanol or dithiothreitol or by heating the serum 
to 630C for 10 minutes. As such, a CDC crossmatch test that is positive against B 
lymphocytes but negative when the same serum is treated with heat at 63°C likely indicates 
an IgM antibody. However, reducing agents or heat can also inactivate low levels of IgG 
antibodies. The significance of the presence of IgM antibodies is not well understood.   
4.3. Caveats to CDC crossmatch testing 
While the standard CDC crossmatch test with B lymphocytes and T lymphocytes has helped 
the transplant community to avoid hyperacute rejection, the test does have some limitations. 
Although lymphocytes express class I HLA and class II HLA molecules, they do not provide 
the full representation of all antigens against which antibodies from a recipient can react. 
Examples to consider are antibodies to MICA or anti-endothelial antibodies. MICA, as 
described previously, are HLA like molecules expressed on the surface of cells with many 
different allelic variations. Importantly, MICA is expressed on many cell lines like 
endothelial cells, dendritic cells, fibroblasts, and epithelial cells but not on lymphocytes. 
Thus, the standard CDC crossmatch tests with B lymphocytes and T lymphocytes are unable 
to detect donor specific antibodies against MICA. In a similar fashion, antibodies against 
donor endothelial cells may also be missed on the standard CDC crossmatch test as the 
targeted antigen may be present on the endothelial cells but not on the lymphocytes.  A 
CDC test with endothelial cells has recently been developed and employed. In reports of 
hyperacute rejection despite a negative CDC crossmatch test, investigation with the 
endothelial cell CDC crossmatch test has revealed the presence of antibodies against donor 
endothelial cells [19]. While it is possible that non-HLA antibodies can cause a hyperacute 
rejection, this is likely a rare event.  
5. Flow cytometry crossmatch test 
Advances in the field of transplantation have led to the development of a more sensitive test 
called the flow cytometry crossmatch test. The flow cytometer utilizes laser-based 
technology to evaluate the status of single cells one at a time. In a flow crossmatch test, cells 
from the potential donor are isolated and are labeled using a fluorescent marker. A 
fluorescent labeled antibody against CD3 or CD19 is used as a marker to distinguish T from 
B lymphocytes. The donor cells are incubated with the recipient’s serum to allow for 
potential antibodies to bind. If there are donor specific anti-HLA antibodies, the Fab portion 
of the antibody binds to the HLA antigens on the cell surface. Fluorescein-labeled goat anti-
human antibody is then used as the reporter fluorescent dye to detect the binding of this 
alloantibody. This secondary antibody can detect either IgG or IgM antibodies. Thus, if there 
is a positive reaction between the recipient’s serum and donor lymphocytes, the flow 
cytometer will be able to detect this interaction as it will recognize the fluorescent-labeled 
anti-CD3 or CD19 antibody and the fluorescent labeled antibody against the Fc portion of 
the donor specific antibody. If there is a negative reaction between the recipient’s serum and 
donor lymphocyte, the flow cytometer will recognize the fluorescent labeled anti-CD3 or 
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CD19 antibody but not detect any fluorescent labeled antibody against the Fc portion of 
donor specific antibody [6].   
The flow crossmatch test has many advantages and is now routinely used prior to renal 
transplantation. It is considered to be more sensitive than the CDC crossmatch test. 
Complement fixation or high-titer antibodies are not required to obtain a positive result. 
During the early years of transplantation, patients continued to experience hyperacute 
rejections despite a negative CDC crossmatch test. Studies using flow crossmatch tests 
found that many acute rejections were associated with a positive flow crossmatch [20]. More 
recent studies have also suggested that transplant recipients with negative flow cytometry 
crossmatch test have better renal survival compared with those with positive flow 
cytometry crossmatch [21,22].   
It is important to note a few caveats in the interpretation of the flow crossmatch test. Flow 
cytometry results are reported as positive or negative based upon the median channel shift 
caused by the binding of a specific antibody. The number of channel shifts required to call a 
test positive or negative varies among laboratories and has not been standardized. Although 
modifications can be made to detect IgM antibodies, typically the standard flow crossmatch 
test only detects IgG that is bound to donor cells. A possible scenario is that the CDC 
crossmatch test is positive against T lymphocytes but negative against T lymphocytes when 
heated to 63°C, thus suggesting the presence of an IgM antibody. The flow crossmatch test will 
be negative as it cannot detect donor specific IgM antibody. Unlike the CDC crossmatch test, 
the flow crossmatch test is also not dependent on complement. A possible scenario is that the 
CDC crossmatch test is negative against T lymphocytes but the flow crossmatch test is positive 
against T lymphocytes. A possible interpretation of these results is that the antibodies that are 
binding to the donor T lymphocytes are non-complement fixing antibodies like IgG2.   
5.1. Significance of a positive flow crossmatch test 
The significance of a positive result in the presence of a negative CDC crossmatch is not 
entirely clear. In the absence of prior sensitization, a positive T or B lymphocyte flow 
crossmatch is not associated with increased risk of acute rejection. In patients who are 
sensitized prior to transplantation, the graft survival is inferior [18]. The outcome of a 
positive B lymphocyte flow crossmatch is less clear [23]. Some studies have not found that a 
positive B lymphocyte flow crossmatch influences graft function. These studies evaluated 
deceased donor transplantations and did not find a difference in the one year and three year 
graft survival [24]. Other studies have found that a positive B lymphocyte flow crossmatch 
test is associated with worse survival. One study evaluated 145 patients and found that 
patients with a positive B lymphocyte flow crossmatch had significantly poorer graft 
survival than those with a negative one (68% vs. 90% at 1 year) [25]. 
6. Panel Reactive Antibody test 
Instead of utilizing donor T lymphocytes and B lymphocytes as used in the standard CDC, 
the panel reactive antibody (PRA) test utilizes a panel of lymphocytes from approximately 
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100 blood donors that represent the local population of potential donors. Percentage of PRA 
is the number of reactions within that panel. This test allows for characterizing the 
sensitization of a recipient. For example, if the serum of a recipient causes lysis of cells and 
hence a positive reaction in 80 out of 100 samples, the PRA is 80%. Theoretically, if a donor 
is available from that donor pool, the recipient would experience acute rejection 80% of the 
time (6). The PRA test, however, is not comprehensive. The panel of individuals does not 
represent all HLA class I and class II molecules. Moreover, the antigen specificity is not 
known. Despite these drawbacks, the PRA test has been extremely useful in providing 
information about the sensitization of a recipient.   
Now, with refinement in technology, it is possible to determine the antigen specificity 
against which an individual produces antibody. These antigens against which an individual 
has antibodies are called unacceptable antigens. Currently, several centers do not perform 
routine PRA and instead calculate the PRA (CPRA). By knowing the frequency of 
unacceptable antigens in the national pool of donors, it is possible to calculate the likelihood 
that a recipient and a donor will be incompatible. Patients with CPRA that is greater than 
80% receive additional points for the allocation of a kidney.   
7. Solid phase assays for donor specific antibodies 
Development of solid phase assays in the past decades has advanced the ability to identify 
antibodies in the blood to specific HLA. Two methods, one based on ELISA and one based 
on fluorescent microspheres (Luminex®), are currently being used to determine the 
presence of HLA class I and HLA class II antibodies.   
In the ELISA method, specific purified HLA molecules are immobilized on a plastic surface. 
The serum of the patient of interest is then incubated on the plastic surface. If there are 
antibodies directed against a specific HLA, these antibody binds to the antigen. A second 
anti-human IgG directed against the Fc portion of antibody is now added to detect the 
serum antibodies that have bound to the HLA. An enzyme is usually attached to this second 
antibody. If the second antibody binds to the Fc portion of the specific anti-HLA antibody, 
addition of a substrate for the attached enzyme will generate a colored product that can be 
quantified.  
In the fluorescent microsphere method, specific synthetic HLA molecules are immobilized 
on fluorescent microspheres. The Luminex® system consists of 100 fluorescently dyed 5.6 
micron-sized polystyrene microspheres. These are internally dyed with red and infrared 
fluorophores. When excited with laser, each microsphere generates a unique spectral 
signature allowing for powerful multiplexing. The serum of the patient of interest is 
incubated with the microspheres coated with HLA molecules. A second fluorescent-labeled 
anti-human IgG directed against the Fc portion of the antibodies is then added to the 
system. A flow cytometer will detect the amount of fluorescent labeled anti-human IgG that 
is bound to a particular HLA molecule. The strength of the antibody titer is quantified as the 
mean fluorescence intensity (MFI).  Currently, Luminex® based anti-HLA detection is 
available as a screen to determine the presence of anti-HLA antibodies (LABScreen PRA) as 
well as to detect the specificity of the antibodies (LABScreen single antigen) [26]. 
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It is important to note some limitations with the solid phase assays. The chosen panel of 
HLA in solid phase assay usually represents the most prevalent HLA in the population and 
so can miss some of the less common HLA. The solid phase assay is also more of “in vitro” 
test as the HLA in the ELISA method and fluorescent microsphere method are not expressed 
on cells but are rather synthetically generated and placed on plastic plate or beads, 
respectively. As such, the solid phase assays will be able to detect HLA in secondary 
structure but may miss detection of antibodies to HLA in quaternary structure as might be 
detected on an assay like the CDC crossmatch test. Commonly used solid phase assays are 
currently designed to detect IgG antibodies and so an IgM antibody can be missed. Finally, 
the solid phase assays does not distinguish complement fixing from non-complement fixing 
antibodies. Despite these limitations, solid phase assays is the most robust test that is 
currently available to detect donor specific antibodies and have provided a wealth of 
information about a recipient’s sensitization to a donor kidney. 
7.1. Significance of donor specific antibodies 
Due to sensitization from prior transplants, pregnancy, or transfusions, potential transplant 
recipients may have preformed donor specific antibody (DSA) against HLA. Several studies 
have examined the significance of having preformed antibodies and have found an 
association with worse graft survival and increased antibody mediated rejection. In one 
study that investigated DSA in over 400 transplant recipients, those with preformed anti-
HLA DSA had inferior graft survival at 8 years as compared with those with no preformed 
DSA (93% vs. 61%) [27]. Another study investigated pre-transplant DSA in 334 patients and 
found a higher incidence of clinical/subclinical antibody mediated rejection in those with 
DSA (55% vs. 6%) [28]. The strength of the DSA as measured by MFI may also play a role in 
the development of antibody mediated rejection [27]. 
While many studies have found that the presence of pre-transplant anti-HLA DSA is a risk 
factor for inferior graft survival and increased AMR, not all anti-HLA DSA may be pathogenic. 
In one study, 30 out of the 67 patients who had anti-HLA DSA did not have a 
clinical/subclinical antibody mediated rejection [28]. Five-year death censored graft survival 
among this group was similar to the transplant patients without anti-HLA DSA.  Clearly, 
further research is needed to elucidate the characteristics of anti-HLA DSA that are pathogenic. 
Transplant recipients may not have anti HLA-DSA prior to the transplant but can develop 
them after transplantation. Similar to preexisting DSA, de novo anti-HLA DSA has been 
found to be a risk factor for graft failure. In an international cooperative study of transplant 
recipients who did not have anti-HLA antibodies prior to transplant, the one-year allograft 
survival after the detection of antibodies was worse among the post transplant recipients 
with de novo anti-HLA antibodies (9%) than among the post transplant recipients with no 
post transplant anti-HLA antibodies (3%) (P<0.001) [29]. 
7.2. Monitoring and treatment 
Transplantation in the presence of preformed anti-HLA DSA is associated with increased 
risk of antibody mediated rejection and graft failure. Transplant centers have utilized 
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desensitization protocols with agents like intravenous immunoglobulin or rituximab to 
reduce the antibody titers prior to transplant. Acceptable patient and graft survival have 
been reported [30]. Furthermore, transplanting highly sensitized patients after 
desensitization may be beneficial as compared to maintaining them on dialysis. One study 
that evaluated 211 HLA sensitized patients found a survival benefit of a desensitization 
protocol as compared with a matched control on dialysis awaiting a deceased donor 
transplant (81% vs. 31% survival at 8 years, P<0.001, respectively) [31]. It is not clear how 
patients who are sensitized and transplanted following desensitization should be 
monitored. One study found that an increase in DSA by one week after transplant following 
desensitization therapy was significantly associated with antibody mediated rejection [32].  
8. Transplant rejection 
Acute rejection continues to remain a significant problem after transplantation. 
Categorization of rejection is based on the Banff classification schema.  In the early 1960’s, 
hyperacute rejection was described in cadaveric kidney transplantations. Shortly after the 
vascular anastomosis, the allograft became cyanotic. On microscopic examination, the major 
findings included neutrophil and platelet margination in glomerular and peritubular 
capillaries, red blood cell stasis, acute tubular necrosis, and variable degree of cortical necrosis. 
Immunofluorescence studies demonstrated the presence of IgG in peritubular capillaries [33]. 
Many of these hyperacute rejections have largely disappeared following the development of 
the CDC crossmatch test. Currently, acute rejection is classified into two major categories: T 
cell mediated acute rejection (ACR) and acute antibody mediated rejection (AMR) (Table 1). 
The following sections will provide an overview of the evolution of the criteria for both 
major types of acute rejection. 
8.1. Renal transplant biopsy adequacy 
The gold standard for diagnosis of transplant rejection is a renal biopsy. Diagnosis of 
transplant rejection depends on the availability of an adequate specimen for evaluation. In 
1991, the Banff schema defined an allograft biopsy specimen as adequate if it contained 
seven or more glomeruli [34]. Further revisions in 1997 required two cores of tissues, 10 or 
more total glomeruli, and the presence of at least two arteries [35]. The presence of seven 
glomeruli and one artery is the threshold for a minimal sample. The diagnosis of acute 
rejection thus depends on an adequate specimen as defined by the Banff criteria.  
8.2. Acute T cell-mediated rejection 
In the 1980’s and 1990’s it was observed that  interstitial inflammation found in transplant 
kidney biopsies, in many cases, had a negligible effect on graft survival and thus was not 
pathognomonic for acute rejection [34]. Tubilitis, the infiltration of lymphocytes into the 
tubules of kidney, was associated with allograft dysfunction and became the hallmark of 
acute rejection. The Banff 1991 consensus defined acute rejection as the involvement of 
tubilitis (>4 mononuclear cells/tubular cross section) and/or intimal arteritis (the infiltration of 
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lymphocytes in the arterial wall). Further revisions of the Banff criteria in 1997 provided a 
classification of acute T cell-mediated rejection that is currently used today [35]. Grade 1A 
rejection requires moderate to severe interstitial inflammation (>25% of parenchyma affected) 
(i2 or i3) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section) (t2). Grade 
1B rejection requires moderate to severe interstitial inflammation (>25% of parenchyma 
affected) (i2 or i3) and severe tubulitis (>10 mononuclear cells/tubular cross section) (t3). Grade 
2A rejection requires intimal arteritis (presence of lymphocytes within the intima) (v1). Grade 
2B rejection requires severe arteritis (involving >25% of luminal area) (v2). Grade 3 rejection 
requires transmural arteritis and/or necrosis of medial smooth muscle cells (v3) (Table 1). 
 
Table 1. Banff Classification of Acute Rejection (adapted from references 35.37.41) 
8.3. Acute antibody mediated rejection  
Feucht et al. reported the presence of complement-split products (C4d) in early biopsies of 
patients with high immunological risk [36]. The Banff 97 classification defined antibody 
mediated rejection as rejection demonstrated to be due, at least in part, to anti-donor 
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antibody. Two forms, immediate and delayed, were recognized. With the description of 
staining for C4d as a marker for antibody mediated rejection, an update to the Banff 97 
classification was reported in 2003 that defined AMR with three characteristics: i) evidence 
of morphological injury in the form of either a) acute tubular necrosis, b) neutrophils and/or 
macrophages in glomeruli or peritubular capillaries or thrombi in glomeruli, or c) intimal 
arteritis/fibrinoid necrosis/intramural inflammation; ii) immunological evidence of antibody 
as either a) presence of C4d in peritubular capillaries or b) immunoglobulins in arterial 
fibrinoid necrosis; and iii) serological evidence of circulating antibodies to donor HLA or 
other endothelial antigens. If 2 out of 3 characteristics are present, the renal biopsy is 
considered suspicious for antibody mediated rejection [35, 37] (Table 1). 
8.4. Borderline changes 
When there is tubulitis and interstitial inflammation but the definition of ACR is not met, 
the biopsy findings are categorized as borderline changes: ‘suspicious’ for acute cellular 
rejection. The criteria for this diagnosis includes: i) no intimal arteritis; ii) mild tubilitis (1 to 
4 mononuclear cells/tubular cross section); iii) at least ‘i1’ inflammation (10-25% of 
parenchyma involved). The significance of borderline biopsies on renal outcomes is not 
clearly defined. One study of 100 kidney allograft biopsies categorized as borderline 
changes found a progressive increase in serum creatinine over time [38]. Nevertheless, 
management of a borderline diagnosis has not been clearly defined. More recently, a study 
that compared 40 borderline changes, 35 T-cell mediated rejection, and 116 nonrejection 
biopsies observed that most cases designated borderline by histopathology were found to be 
nonrejection by molecular phenotyping [39].  
8.5. Other types of acute rejection 
ACR and AMR are not mutually exclusive and frequently coexist. In a study of 87 patients 
with C4d positive AMR as defined by Banff criteria, 32 (37%) had evidence of concurrent 
ACR. The presence of concurrent ACR was an independent risk factor of allograft failure in 
kidney transplant recipients with C4d positive acute AMR [40]. It is important to emphasize 
that Banff criteria are not all-inclusive. Plasma-cell rich acute rejection is an entity where the 
interstitial inflammation and tubulitis are predominantly composed of plasma cells in 
addition to lymphocytes. Allergic interstitial nephritis closely resembles ACR and are all not 
always associated with eosinophil infiltrates. Thus, morphologically, it may be also be 
useful to categorize acute rejection as (i) interstitial rejection characterized predominantly by 
interstitial inflammation and tubulitis, (ii) vascular rejection characterized predominantly by 
intimal arteritis and (iii) capillary rejection characterized predominantly by glomerulitis and 
peritubular capillary inflammation usually in the presence of circulating DSA.  
8.6. Chronic rejection 
The Banff classification also defined three forms of chronic rejection: (i) chronic active T cell-
mediated rejection characterized by arterial intimal fibrosis with mononuclear cell 
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infiltration in fibrosis and  formation of neo-intima, and (ii) chronic active antibody-
mediated rejection characterized by C4d+, presence of circulating antidonor antibodies, and 
morphologic evidence of chronic tissue injury, such as glomerular double contours and/or 
peritubular capillary basement membrane multilayering and/or interstitial fibrosis/tubular 
atrophy and/or fibrous intimal thickening in arteries, and (iii) interstitial fibrosis and tubular 
atrophy without evidence of any specific etiology that may also include nonspecific vascular 
and glomerular sclerosis [41]. Morphological evidence of chronic active antibody mediated 
tissue injury but with negative C4d is being increasingly recognized.  
9. Non-invasive molecular techniques for assessing acute rejection 
The platforms for molecular based biomarker discovery and validation are: (i) Real-time 
polymerase chain reaction (RT-PCR), Microarray and RNA sequencing (detection of 
expression of single or multiple genes), (ii) Elisa and protein microarray (detection of single 
or multiple proteins), (iii) ELISPOT (detection of cytokine producing cells), (iv) Immuknow 
(detection of adenosine triphosphate [ATP] levels in activated T-lymphocytes), and (v) 
Luminex® (detection of cytokines or alloantibodies) [42]. 
Urinary cell and peripheral blood cell messenger RNA (mRNA) profiling of transplant 
recipients has been studied extensively as a tool for the noninvasive diagnosis and 
prognosis of kidney transplant rejection. This technique involves quantification of mRNA 
levels of mechanistically informative genes using RT-PCR assay from urinary cells or 
peripheral blood cells of kidney transplant recipients. As an example, measurement of 
granzyme B and perforin (m) mRNA activity in urinary cells has been reported to be a 
sensitive and specific marker for the detection of acute cellular rejection [43].  In a study of 
83 kidney transplant recipients; 36 with acute rejection, 18 with chronic allograft 
nephropathy, and 29 with normal biopsy results, urinary cell mRNA levels of regulatory T-
lymphocyte marker, FoxP3, quantified at the time of biopsy diagnosis predicted reversal of 
acute rejection with 90 percent sensitivity and 73 percent specificity. Urinary cell mRNA 
levels of FoxP3 also identified subjects at risk for graft failure within six months after the 
incident episode of acute rejection. Urinary cell mRNA levels of CD3 (marker of T 
lymphocytes), CD25 (marker of activated T-lymphocytes), and perforin did not predict 
rejection reversal or graft failure [44]. Recently, a large multi-center trial sponsored by the 
National Institutes of Health trial validated the utility of urinary cell mRNA levels in the 
diagnosis of ACR [45]. The role of urinary cell mRNA level as a noninvasive tool is not 
limited to the diagnosis of acute rejection. A recent study identified a urinary cell mRNA 
signature for the diagnosis of fibrosis in human kidney allografts [46]. 
The Cylex Immuknow assay is an FDA approved blood test for the detection of cell 
mediated immune response in populations undergoing immunosuppressive therapy for 
organ transplants. The test quantifies the amount of ATP produced by lymphocytes of the 
transplant recipient upon activation. Based on the ATP levels there are two cut-off values: 
≤225 ng/ml represents a low immune cell response and ≥525 ng/ml represents a strong 
immune cell response. In between values represent moderate immune cell response. Some 
studies have found a relation between the Cylex Immuknow assay and acute rejection [47]. 
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However, more recently, a study that evaluated 1330 ImmuKnow assay values in 583 renal 
transplant recipients at a single center from 2004 to 2009 failed to show an association 
between single time point ImmuKnow assay values and the subsequent development of an 
adverse event (acute rejection or opportunistic infections) in the subsequent 90 days [48].  
In a recent study of 64 kidney transplant recipients with graft dysfunction, a panel of 21 
cytokines secreted by peripheral blood mononuclear cells was assayed using the Luminex® 
platform. In the initial training cohort of 32 patients, IL-6 was the best predictor of acute 
rejection. In the validation cohort of 32 patients, IL-6 predicted acute rejection, using a 
training set derived cut-point, with 92% sensitivity and 63% specificity [49].  
Rapid advancements in our understanding of the role of microRNAs in transplantation [50] 
and in molecular techniques such as RNA sequencing have opened up new avenues for 
biomarker discovery and has resulted in better insight on the mechanistic basis of allograft 
dysfunction. In the future, we anticipate personalized management of transplant recipients 
with a combination of traditional pathology and the ‘omics’ based approach (genomics, 
proteomics, and metabolomics). 
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